Literature DB >> 12060640

Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin.

Bharat H Joshi1, Koji Kawakami, Pamela Leland, Raj K Puri.   

Abstract

Squamous cell carcinoma of the head and neck (SCCHN) is characterized by a high proliferation index and marked propensity for local invasion resulting in poor prognosis for these patients. To develop tumor-targeted novel therapeutic agents, here we demonstrate that SCCHN cell lines express receptors for an immune regulatory cytokine, interleukin (IL) 13. By reverse transcription-PCR (RT-PCR), we found that 16 SCCHN cell lines express equally strong RT-PCR positive bands for mRNA of IL-13Ralpha1 and IL-4Ralpha chains. However, only three cell lines, HN12, YCUM911, and KCCT873, expressed a strong band for transcripts for IL-13Ralpha2 chain and five cell lines, YCUL891, KCCTC871, KCCL871, KCCTCM901, and RPMI 2650 expressed faint bands. Transcripts for IL-2Rgamma(c) chain were absent in all of the cell lines tested. Indirect immunofluorescence analysis for four different receptor chains confirmed RT-PCR results and showed pronounced expression of IL-13Ralpha2 protein in three high IL-13R expressing cell lines. All of the cell lines were equally positive for IL-13Ralpha1 and IL-4Ralpha chains. Receptor-binding studies demonstrated that IL-13Ralpha2-positive cell lines expressed a high density of IL-13 receptors. Using two chimeric proteins composed of IL-13 and mutated forms of Pseudomonas exotoxin (IL-13-PE38 or IL-13-PE38QQR), we found that these two fusion toxins were highly and equally cytotoxic to IL-13Ralpha2-positive SCCHN, whereas IL-13Ralpha2-negative cell lines showed low or no sensitivity to IL-13 toxins. To additionally substantiate the critical role of the IL-13Ralpha2 chain in IL-13R-mediated cytotoxicity, two head and neck tumor cell lines (YCUMS861 and KB), devoid of the transcripts of this chain, were transfected with IL-13Ralpha2 cDNA and then tested for cytotoxicity. Transient transfection of the IL-13Ralpha2 chain highly sensitized these cells to IL-13 toxin as compared with mock-transfected control cells. Thus, our results indicate that IL-13Ralpha2 is present in 50% SCCHN tumor cell lines; of these, 19% are high expresser for this chain and respond to IL-13 cytotoxin. Thus, IL-13 cytotoxin may be a useful agent for high IL-13R-expressing SCCHN.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12060640

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   13.801


  21 in total

1.  Genetic reprogramming of tumor cells by zinc finger transcription factors.

Authors:  Pilar Blancafort; Emily I Chen; Beatriz Gonzalez; Sharon Bergquist; Andries Zijlstra; Daniel Guthy; Arndt Brachat; Ruud H Brakenhoff; James P Quigley; Dirk Erdmann; Carlos F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-04       Impact factor: 11.205

2.  Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation.

Authors:  Larisa J Geskin; Sara Viragova; Donna B Stolz; Patrizia Fuschiotti
Journal:  Blood       Date:  2015-01-27       Impact factor: 22.113

3.  Specific targeting of human interleukin (IL)-13 receptor α2-positive cells with lentiviral vectors displaying IL-13.

Authors:  Wu Ou; Michael P Marino; Akiko Suzuki; Bharat Joshi; Syed R Husain; Andrea Maisner; Evanthia Galanis; Raj K Puri; Jakob Reiser
Journal:  Hum Gene Ther Methods       Date:  2012-05-21       Impact factor: 2.396

Review 4.  New delivery approaches for pediatric brain tumors.

Authors:  Ian F Pollack; Robert Keating
Journal:  J Neurooncol       Date:  2005-12       Impact factor: 4.130

5.  Clinical development of experimental therapies for malignant glioma.

Authors:  Nikolai G Rainov; Volkmar Heidecke
Journal:  Sultan Qaboos Univ Med J       Date:  2011-02-12

6.  Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity.

Authors:  Cory Allen; Georgia Paraskevakou; Ianko Iankov; Caterina Giannini; Mark Schroeder; Jann Sarkaria; Mark Schroeder; Raj K Puri; Stephen J Russell; Evanthia Galanis
Journal:  Mol Ther       Date:  2008-07-29       Impact factor: 11.454

7.  Overexpression of interleukin-13 receptor-alpha2 in neuroendocrine malignant pheochromocytoma: a novel target for receptor directed anti-cancer therapy.

Authors:  Edwin W Lai; Bharat H Joshi; Lucia Martiniova; Ritika Dogra; Toshio Fujisawa; Pamela Leland; Ronald R de Krijger; Irina A Lubensky; Abdel G Elkahloun; John C Morris; Raj K Puri; Karel Pacak
Journal:  J Clin Endocrinol Metab       Date:  2009-06-02       Impact factor: 5.958

Review 8.  Diphtheria toxin-based targeted toxin therapy for brain tumors.

Authors:  Yan Michael Li; Daniel A Vallera; Walter A Hall
Journal:  J Neurooncol       Date:  2013-05-22       Impact factor: 4.130

9.  Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model.

Authors:  D A Vallera; B J Stish; Y Shu; H Chen; A Saluja; D J Buchsbaum; S M Vickers
Journal:  Gut       Date:  2008-01-25       Impact factor: 23.059

10.  Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors.

Authors:  John H Sampson; Gamal Akabani; Gary E Archer; Darell D Bigner; Mitchel S Berger; Allan H Friedman; Henry S Friedman; James E Herndon; Sandeep Kunwar; Steve Marcus; Roger E McLendon; Alison Paolino; Kara Penne; James Provenzale; Jennifer Quinn; David A Reardon; Jeremy Rich; Timothy Stenzel; Sandra Tourt-Uhlig; Carol Wikstrand; Terence Wong; Roger Williams; Fan Yuan; Michael R Zalutsky; Ira Pastan
Journal:  J Neurooncol       Date:  2003-10       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.